Specialists & Providers
Diagnostic Biomarkers
Diagnostic & Clinical Standards
Authoritative clinical thresholds and screening guidelines from major medical bodies.
Adult BMI Categories
CDC2025
Body Mass Index (BMI) is a screening measure calculated from height and weight. The CDC classifies adult BMI into four main categories: underweight (below 18.5), healthy weight (18.5 to 24.9), overweight (25.0 to 29.9), and obesity (30.0 or higher).
BMI below the healthy weight range. May indicate nutritional deficiency or underlying health issues.
BMI within the range generally associated with lower health risks at the population level.
BMI above the healthy weight range. Associated with increased risk of certain health conditions at the population level.
BMI in the obesity range. Associated with higher risk of type 2 diabetes, cardiovascular disease, and other health conditions.
Obesity Classes I-III
CDC2025
Within the obesity BMI range (30 or higher), the CDC further classifies obesity into three classes: Class 1 (BMI 30 to 34.9), Class 2 (BMI 35 to 39.9), and Class 3 or severe obesity (BMI 40 or higher).
Lowest severity obesity class. Risk of obesity-related comorbidities is elevated above the overweight category.
Moderate severity obesity. Significantly elevated risk of obesity-related comorbidities.
Highest severity obesity class (also called severe or morbid obesity). Substantially increased risk of mortality and morbidity. May indicate candidacy for bariatric surgery evaluation.
Treatments & Interventions
Benzfetamine hydrochloride
substance
Phentermine hydrochloride
substance
Phendimetrazine tartrate
substance
Amfepramone hydrochloride
substance
Benzfetamine
substance
Phendimetrazine
substance
Phentermine
substance
Sibutramine
substance
Orlistat
substance
Phenmetrazine
substance
Mazindol
substance
Fenfluramine hydrochloride
substance
Diethylpropion
substance
Methamphetamine hydrochloride
substance
Phenylpropanolamine hydrochloride
substance
Fenfluramine
substance
Phenmetrazine hydrochloride
substance
Phenylpropanolamine
substance
Methamphetamine
substance
Sibutramine hydrochloride monohydrate
substance
Clinical Trials
Recent Trials
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
Advancing Biopsychosocial Care Training Initiative
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
Research Evidence
Peer-reviewed studies linked via MeSH term "Obesity" from the MEDLINE/PubMed database.
Research data from MEDLINE/PubMed
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Related Conditions
Quick Facts
- SNOMED CT
- 414916001
- UMLS CUI
- C0028754
- Fully Specified Name
- Obesity (disorder)
- Specialists
- 3
- Diagnostic Biomarkers
- 3
- HPO Phenotypes
- 3
- Known Treatments
- 20
- Clinical Trials
- 426
Related Health Goals
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.